Tevogen Bio Holdings Inc.(TVGN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 29 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
TVGN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Tevogen Bio Holdings Inc. (TVGN), a Healthcare sector company. TVGN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 29 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), Tevogen Bio Holdings Inc. reports net income of $-5.4M, free cash flow of $-2.7M. Top institutional holders of TVGN by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, BlackRock,, MORGAN STANLEY, based on the most recent SEC filings. TVGN trades on the Nasdaq exchange and files with the SEC under CIK 1860871. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TVGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tevogen Bio Holdings Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-5.4M
Free Cash Flow
Q1 2026
$-2.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+77.3% YoYOperating Income
-505.7% YoYEPS (Diluted)
-46.3% YoYTotal Assets
-37.1% YoYTotal Debt
Op. Cash Flow
-46.8% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Net Income | $-13.7M +77.3% | $-60.5M -1471.9% | $4.4M | — |
| Operating Income | $-53.6M -505.7% | $-8.8M | — | — |
| EPS (Diluted) | $-3.50 -46.3% | $-2.39 | — | — |
| Total Assets | $3.5M -37.1% | $5.5M -98.5% | $357.1M +1.2% | $352.9M |
| Total Debt | — | — | $0.00 | — |
| Operating Cash Flow | $-12.0M -46.8% | $-8.2M -3693.6% | $-215.4K | — |
AI Insight: TVGN Financial Trends
Pre-revenue biotech burning $5–10M quarterly with deteriorating equity position; no meaningful operational improvement.
• Net income losses narrowed from $10M in Q1 2025 to $5M in Q4 2025 and Q1 2026, suggesting cost discipline.
• Operating cash burn remains stuck at $2–4M per quarter with no clear trend improvement across eight quarters.
• Equity deteriorated to negative $10M in Q1 2026 from negative $6M in Q3 2024, signaling cumulative dilution.
⚠ Zero revenue reported across entire period; company is purely R&D-focused with no commercial traction visible.
⚠ Negative equity worsening; company approaching balance-sheet crisis without disclosed funding or partnership announcements.
AI Insight: TVGN Ratio Trends
Insufficient data to assess financial trends—all ratio metrics are missing across the entire period.
• No operating margin, net profit margin, ROE, ROA, ROIC, or leverage data available for any quarter Q2 2024 through Q1 2026.
⚠ Complete absence of profitability and efficiency metrics prevents assessment of operational health or shareholder value creation.
Get alerted when TVGN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Tevogen Bio Holdings Inc. including:
Top Institutional Holders of TVGN
VANGUARD CAPITAL MANAGEMENT LLC
$150.3K33,248 shBlackRock, Inc.
$110.3K24,395 shMORGAN STANLEY
$78.3K17,334 shGEODE CAPITAL MANAGEMENT, LLC
$71.1K15,734 shDEUTSCHE BANK AG\
$69.3K15,324 shFMR LLC
$45.9K10,157 shRussell Investments Group, Ltd.
$26.2K5,806 shVANGUARD PORTFOLIO MANAGEMENT LLC
$20.5K4,525 shUBS Group AG
$16.1K3,567 shVANGUARD FIDUCIARY TRUST CO
$6.2K1,368 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $150.3K | 33,248 |
| BlackRock, Inc. | $110.3K | 24,395 |
| MORGAN STANLEY | $78.3K | 17,334 |
| GEODE CAPITAL MANAGEMENT, LLC | $71.1K | 15,734 |
| DEUTSCHE BANK AG\ | $69.3K | 15,324 |
| FMR LLC | $45.9K | 10,157 |
| Russell Investments Group, Ltd. | $26.2K | 5,806 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $20.5K | 4,525 |
| UBS Group AG | $16.1K | 3,567 |
| VANGUARD FIDUCIARY TRUST CO | $6.2K | 1,368 |
More Healthcare Companies
View all Healthcare →Put TVGN on your watchlist
Track score changes the day Tevogen Bio Holdings Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TVGN a good stock to buy?
13F Pro's AI-powered analysis of Tevogen Bio Holdings Inc. (TVGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TVGN are available on the TVGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own TVGN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TVGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Tevogen Bio Holdings Inc.'s investment landscape.